Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.

@article{McCollum2003CostAO,
  title={Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species.},
  author={Marianne McCollum and David C. Rhew and Stephen Parodi},
  journal={Clinical therapeutics},
  year={2003},
  volume={25 12},
  pages={3173-89}
}
BACKGROUND Infections with methicillin-resistant Staphylococcus species (MRSS) are associated with higher treatment costs than infections with methicillin-sensitive Staphylococcus species in the United States--partly because of an increased length of hospital stay (LOS). OBJECTIVE This study used pharmacoeconomic modeling to evaluate the costs and outcomes associated with the use of i.v. vancomycin compared with p.o. linezolid in the treatment of MRSS-infected patients. METHODS A… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Pharmacoeconomics of linezolid.

Expert opinion on pharmacotherapy • 2008
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…